表紙
市場調査レポート

スタチンの世界市場:2015年〜2019年

Global Statin Market 2015-2019

発行 TechNavio (Infiniti Research Ltd.) 商品コード 335151
出版日 ページ情報 英文 81 Pages
即納可能
価格
本日の銀行送金レート: 1USD=101.50円で換算しております。
Back to Top
スタチンの世界市場:2015年〜2019年 Global Statin Market 2015-2019
出版日: 2015年07月08日 ページ情報: 英文 81 Pages
概要

世界のスタチン市場は、2014年〜2019年のCAGRで、7.50%の成長が見込まれています。

当レポートでは、世界のスタチン市場について調査分析し、市場規模と成長率、市場動向、市場促進要因・課題、市場機会について検証するほか、主要ベンダーなどについて、体系的な情報を提供しています。

第1章 エグゼクティブサマリー

第2章 略語リスト

第3章 調査範囲

  • 市場概要
  • 主な製品

第4章 市場調査手法

  • 市場調査プロセス
  • 調査手法

第5章 製品プロファイル

  • クレストール
  • カデュエット
  • レスコール
  • リピトール
  • リプトルゼット
  • メバコール
  • バイトリン
  • ゾコール

第6章 イントロダクション

第7章 スタチン:概要

  • スタチンファーマコフォア
  • 作用機序
  • 臨床応用
  • 治療ガイドライン

第8章 パイプラインポートフォリオ

  • HL040
  • Livasartan
  • BCWP-C001
  • CJ-30056

第9章 市場情勢

  • 市場概要
    • 市場規模と予測
  • 米国のスタチン市場
    • 市場規模と予測
  • ファイブフォース分析

第10章 市場区分:製品カテゴリー別

  • 1型スタチン
  • 2型スタチン

第11章 地域区分

  • 世界のスタチン市場:地域区分別

第12章 購入基準

第13章 市場成長促進要因

第14章 成長促進要因とその影響

第15章 市場の課題

第16章 成長促進要因と課題の影響

第17章 市場動向

第18章 動向とその影響

第19章 ベンダー情勢

  • 競合シナリオ
  • 市場シェア分析
  • その他の有力ベンダー

第20章 主要ベンダーの分析

  • AstraZeneca
  • Merck
  • Novartis
  • Pfizer

第21章 関連レポート

図表

目次
Product Code: IRTNTR6430

About Statin

Statin is a structural analog of HMG-CoA enzyme and is effective in reducing LDL. It shows its pharmaceutical action by inhibiting the key enzyme involved in cholesterol synthesis, which is called HMG-CoA reductase. Therefore, statin is referred to HMG-CoA reductase inhibitors. Statin has been associated with a beneficial effect on cardiovascular morbidity and mortality. It has significant anti-inflammatory and plaque-stabilizing effects. Its other effects include decreased oxidative stress and vascular inflammation with increased atherosclerotic lesions. Some of the currently available statins are atorvastatin, lovastatin, rosuvastatin, and simvastatin.

Technavio's analysts forecast the global statin market to decline at a CAGR of 7.50% over the period 2014-2019.

Covered in this Report

This report covers the present scenario and the growth prospects of the global statin market for the period 2015-2019. To calculate the market size, the report considers revenue generated from the sales of statins used for the management of lipid abnormalities and lipid-associated comorbidities such as stroke and coronary heart disease. This report provides a discussion of the market in the following three regions: Americas, APAC, and EMEA.

Technavio's report, Global Statin Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects in the coming years. The report includes a discussion of the key vendors operating in this market.

Key Regions

  • Americas
  • APAC
  • EMEA

Key Vendors

  • AstraZeneca
  • Merck
  • Novartis
  • Pfizer

Other Prominent Vendors

  • Amgen
  • Aurobindo Pharma
  • Abbvie
  • Abbott
  • Biocon
  • BC World Pharm
  • Cipla
  • Concord Biotech
  • CKD Bio
  • CJ HealthCare Corporation
  • Cerenis Therapeutics
  • GlaxoSmithKline
  • HanAll BioPharma
  • JX Pharmaceuticals
  • Kowa
  • Lupin
  • Livzon
  • Mylan
  • Merz Pharmaceuticals
  • SUN Pharma
  • Teva
  • Torrent Pharmaceuticals
  • Zydus Cadila

Market Driver

  • Rising Number of High Cholesterol Cases
  • For a full, detailed list, view our report

Market Challenge

  • Lack of Novel Molecules in Statins Category
  • For a full, detailed list, view our report

Market Trend

  • Switch from Statins to Non-statins
  • For a full, detailed list, view our report

Key Questions Answered in this Report

  • What will the market size be in 2019 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?

Table of Contents

01. Executive Summary

02. List of Abbreviations

03. Scope of the Report

  • 03.1. Market Overview
  • 03.2. Product Offerings

04. Market Research Methodology

  • 04.1. Market Research Process
  • 04.2. Research Methodology

05. Product Profile

  • 05.1. Crestor
  • 05.2. Caduet
  • 05.3. Lescol
  • 05.4. Lipitor
  • 05.5. Liptruzet
  • 05.6. Mevacor
  • 05.7. Vytorin
  • 05.8. Zocor

06. Introduction

07. Statin: An Overview

  • 07.1. Statin Pharmacophore
  • 07.2. Mechanism of Action
    • 07.2.1. Different Class of Lipoproteins
  • 07.3. Clinical Application
  • 07.4. Treatment Guidelines

08. Pipeline Portfolio

  • 08.1. HL040
  • 08.2. Livasartan
  • 08.3. BCWP-C001
  • 08.4. CJ-30056

09. Market Landscape

  • 09.1. Market Overview
    • 09.1.1. Market Size and Forecast
  • 09.2. Statin Market in US 2014-2019
    • 09.2.1. Market Size and Forecast
  • 09.3. Five Forces Analysis

10. Market Segmentation by Product Category

  • 10.1. Type 1 Statins
    • 10.1.1. Lovastatin
    • 10.1.2. Pravastatin
    • 10.1.3. Simvastatin
  • 10.2. Type 2 Statins
    • 10.2.1. Atorvastatin
    • 10.2.2. Fluvastatin
    • 10.2.3. Rosuvastatin

11. Geographical Segmentation

  • 11.1. Global Statin Market by Geographical Segmentation 2014-2019

12. Buying Criteria

13. Market Growth Drivers

14. Drivers and their Impact

15. Market Challenges

16. Impact of Drivers and Challenges

17. Market Trends

18. Trends and their Impact

19. Vendor Landscape

  • 19.1. Competitive Scenario
    • 19.1.1. Key News
    • 19.1.2. Mergers and Acquisitions
  • 19.2. Market Share Analysis 2014
    • 19.2.1. AstraZeneca
    • 19.2.2. Merck
    • 19.2.3. Novartis
    • 19.2.4. Pfizer
  • 19.3. Other Prominent Vendors

20. Key Vendor Analysis

  • 20.1. AstraZeneca
    • 20.1.1. Key Facts
    • 20.1.2. Business Overview
    • 20.1.3. Business Segmentation by Revenue 2013
    • 20.1.4. Business Segmentation by Revenue 2011-2013
    • 20.1.5. Sales by Geography
    • 20.1.6. Business Strategy
    • 20.1.7. Key Developments
    • 20.1.8. SWOT Analysis
  • 20.2. Merck
    • 20.2.1. Key Facts
    • 20.2.2. Business Overview
    • 20.2.3. Business Segmentation by Revenue 2013
    • 20.2.4. Business Segmentation by Revenue 2012 and 2013
    • 20.2.5. Sales by Geography
    • 20.2.6. Business Strategy
    • 20.2.7. Key Developments
    • 20.2.8. SWOT Analysis
  • 20.3. Novartis
    • 20.3.1. Key Facts
    • 20.3.2. Business Description
    • 20.3.3. Business Segmentation
    • 20.3.4. Revenue by Business Segmentation
    • 20.3.5. Revenue Comparison 2012 and 2013
    • 20.3.6. Sales by Geography
    • 20.3.7. Business Strategy
    • 20.3.8. Key Developments
    • 20.3.9. SWOT Analysis
  • 20.4. Pfizer
    • 20.4.1. Key facts
    • 20.4.2. Business Overview
    • 20.4.3. Business Segmentation by Revenue 2014
    • 20.4.4. Business Segmentation by Revenue 2013 and 2014
    • 20.4.5. Geographical Segmentation by Revenue 2014
    • 20.4.6. Business Strategy
    • 20.4.7. Key Developments
    • 20.4.8. SWOT Analysis

21. Other Reports in this Series

List Of Exhibits

  • Exhibit 1: Market Research Methodology
  • Exhibit 2: Pictorial Representation of Statin Pharmacophore
  • Exhibit 3: Schematic Representation of Statin and Effect on Cholesterol Synthesis
  • Exhibit 4: Evaluation of Lipoprotein Levels based on ATP III Classification
  • Exhibit 5: Diagrammatic Representation of Pipeline Molecules for Lipid Management
  • Exhibit 6: Global Statin Market 2014-2019 ($ millions)
  • Exhibit 7: Statin Market in US 2014-2019 ($ millions)
  • Exhibit 8: Global Statin Market Segmentation by Molecule Type
  • Exhibit 9: Segmentation of Global Statin Market by Geography 2014
  • Exhibit 10: Arguments For and Against OTC Switch by Pharmaceutical Companies and Regulatory Organizations
  • Exhibit 11: Crestor: YoY Global Revenue 2010-2014 ($ millions)
  • Exhibit 12: AstraZeneca: Key Takeaways
  • Exhibit 13: Vytorin: YoY Global Revenue of 2010-2014 ($ millions)
  • Exhibit 14: Zocor: YoY Global Revenue 2010-2014 ($ millions)
  • Exhibit 15: Merck: Key Takeaways
  • Exhibit 16: Lipitor: YoY Global Revenue of 2010-2014 ($ millions)
  • Exhibit 17: Pfizer: Key Takeaways
  • Exhibit 18: AstraZeneca: Business Segmentation by Revenue 2013
  • Exhibit 19: AstraZeneca: Business Segmentation by Revenue 2011-2013 ($ millions)
  • Exhibit 20: AstraZeneca: Sales by Geography 2013
  • Exhibit 21: Merck: Business Segmentation by Revenue 2013
  • Exhibit 22: Merck: Business Segmentation by Revenue 2012 and 2013 ($ billions)
  • Exhibit 23: Merck: Sales by Geography 2013
  • Exhibit 24: Novartis: Business Segmentation
  • Exhibit 25: Novartis: Revenue by Business Segmentation 2013
  • Exhibit 26: Novartis: Revenue by Business Segmentation 2012 and 2013 ($ millions)
  • Exhibit 27: Novartis: Revenue by Geographical Segmentation 2013
  • Exhibit 28: Pfizer: Business Segmentation by Revenue 2014
  • Exhibit 29: Pfizer: Business Segmentation by Revenue 2013 and 2014 ($ billions)
  • Exhibit 30: Pfizer: Geographical Segmentation by Revenue 2014
Back to Top